Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.

Phase I trial data show that pegylated arginine deiminase is well tolerated, with a high response rate, when used in combination with cisplatin and pemetrexed to treat patients with argininosuccinate synthetase 1-deficient thoracic cancers.

Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies.

Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.

A quick guide to the JAVELIN clinical trials investigating the efficacy and safety of the PD-L1 inhibitor avelumab in the lung cancer setting.

There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR -mutated, early-stage non-small-cell lung cancer, show trial results.

The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

Two sets of guidance on the care of lung cancer patients during the COVID-19 pandemic have been issued.

Cemiplimab monotherapy offers a significant overall survival benefit compared with platinum-doublet chemotherapy for advanced non-small-cell lung cancer patients with a PD-L1 tumor cell expression of 50% or above, indicate initial EMPOWER-Lung 1 trial findings.

Erin Schenk highlights some of the lung cancer immuno-oncology studies that you may have missed at the virtual 2020 ASCO Annual Meeting (8:23).

In light of the severity of the viral disease, “most patients with cancer were recommended to withdraw cancer treatment after infection,” the investigators write in the Journal of Thoracic Oncology .

Individuals at high risk for developing lung cancer benefit from periodic screening with low-dose computed tomography, indicate the 10-year results from the NELSON trial.

Between 2010 and 2014, more than a third of lung cancer patients in the USA received less intensive treatment than recommended, or indeed no treatment at all, shows an analysis of data from the US National Cancer Database.

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.

Digital next-generation sequencing of circulating tumor DNA is a clinically useful option for advanced lung adenocarcinoma patients with insufficient tumor biopsy samples, say researchers.